Mobile

A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004774-85

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The objective of this study is to determine whether therapy with rituximab alters the immune response in relapsed or refractory, low-grade or follicular, CD20+, B-cell NHL subjects in comparison to untreated, age-matched control subjects. The primary endpoint of the study is to determine whether treatment with rituximab causes a clinically significant effect on immunological recall response to tetanus vaccine in NHL subjects.

Critère d'inclusion

  • Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)

Liens